“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b 4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s425. Accessed May 19, 2025. https://skin.dermsquared.com/skin/article/view/3101.